Mean change in chloride transport from baseline to end of treatment low dose: −6.8 mV (p = 0.004) high dose: −3.4 mV (p = 0.025) combined groups: −5.4 mV (p < 0.001) CF = cystic fibrosis ...
The treatment is designed to address the underlying cause of cystic fibrosis by delivering a therapeutic gene that allows lung cells to make a working CFTR protein and prevention infection.
The initiative, conducted in collaboration with Intellia Therapeutics, aims to develop new treatments for cystic fibrosis (CF), including for patients with genotypes that are non-responsive or ...